New NET Cancer drug in the pipeline – Fosbretabulin Tromethamine CA4P (from Oxigene)

Ronny Allan - Living with Neuroendocrine Cancer

GoodNewsIt’s always nice to hear that another treatment for Neuroendocrine Cancer is in the pipeline and another great start to 2016.  I had not heard of the one that’s currently in the news, so rather than just retweet and share, I decided to do some detective work and then share with you a much greater understanding of what this drug is and what it has the potential to do.  My initial thoughts are that it looks promising but it’s still ‘early days’.

The new drug is formally known as Fosbretabulin Tromethamine or just Fosbretabulin.  It also goes by the name of Combretastatin or CA4P which translates to Combretastatin A4-phosphate.  In the most basic of terms it’s a type of vascular disrupting agent (VDA).  It appears to be something currently targeted at patients with advanced Pancreatic or Gastrointestinal Neuroendocrine Tumours with elevated biomarkers (CgA, 5HIAA, Pancreastatin etc).  The drug is currently…

View original post 473 more words

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s